Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells / 癌症
Chinese Journal of Cancer
;
(12): 178-184, 2012.
Article
Dans Anglais
| WPRIM
| ID: wpr-294437
ABSTRACT
Niclosamide, an oral antihelminthic drug, has been used to treat tapeworm infection for about 50 years. Niclosamide is also used as a molluscicide for water treatment in schistosomiasis control programs. Recently, several groups have independently discovered that niclosamide is also active against cancer cells, but its precise mechanism of antitumor action is not fully understood. Evidence supports that niclosamide targets multiple signaling pathways (NF-κB, Wnt/β-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells. The exciting advances in elucidating the antitumor activity and the molecular targets of this drug will be discussed. A method for synthesizing a phosphate pro-drug of niclosamide is provided. Given its potential antitumor activity, clinical trials for niclosamide and its derivatives are warranted for cancer treatment.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anatomopathologie
/
Pharmacologie
/
Cellules souches tumorales
/
Pharmacocinétique
/
Transduction du signal
/
Mouvement cellulaire
/
Facteur de transcription NF-kappa B
/
Espèces réactives de l'oxygène
/
Lignée cellulaire tumorale
/
Complexes multiprotéiques
Limites du sujet:
Animaux
/
Humains
langue:
Anglais
Texte intégral:
Chinese Journal of Cancer
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS